Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576678 · ClinicalTrials.gov registry record · Phase 2
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
A Phase 2 study of Psoriasis, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 18
- Study locations
NCT02576678 is a Phase 2 study of Psoriasis that has completed, run by Amgen. The registered enrollment target is 42 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (91% lower). The trial reports 18 study locations across 9 states.
The verdict
NCT02576678, a Phase 2 study of Psoriasis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label study in subjects with moderate to severe plaque psoriasis aged 6 to 17 years, inclusive, intended to assess the safety, tolerability, and PK of apremilast with 2 weeks of oral apremilast treatment followed by a 48-week extension of apremilast treatment. Moderate to severe plaque psoriasis is defined as Psoriasis Area Severity Index (PASI) ≥ 12, Body Surface Area (BSA) ≥ 10%, and static Physician Global Assessment (sPGA) of ≥ 3. The total study duration for each subject will last for up to a total of 107 weeks which includes screening, treatment (including the PK portion of the study and the extension treatment period), two short-term follow-up periods and a long-term follow-up period.
Conditions Studied
Interventions
- DRUG Apremilast
Study Locations (18)
Other
- Rheinische Friedrich-Wilhelms-Universitaet Bonn - Universitaetsklinikum Bonn - Bonn
- Universitatsklinikum Essen - Essen
- Universitatsklinikum Klinikum Frankfurt Main - Frankfurt
- Kinderkrankenhaus Wilhelmstift, Dermatologie - Hamburg
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Mainz
- Muenster University Hospital (Universitätsklinikum Muenster) - Münster
- Hospital de la Santa Creu i Sant Pau - Barcelona
- Hospital Sant Joan de Deu - Esplugues de Llobregat
- Hospital La Paz - Madrid
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago Department of Dermatology - Chicago
- Dundee Dermatology - West Dundee
California
- Rady Children's Hospital - San Diego
Georgia
- Emory University - Atlanta
New York
- Mount Sinai, St. Luke's - New York
Texas
- Texas Dermatology and Laser Specialists - San Antonio
Alberta
- Stollery Children's Hospital - Edmonton
Newfoundland and Labrador
- Nexus Clinical Research - St. John's
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2019-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576678
The ClinicalTrials.gov registry entry for NCT02576678 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (91% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.
NCT02576678 reports 18 study locations spanning 9 distinct geographic areas - top geographies include Other, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT02576678 about?
NCT02576678 is a clinical study titled "A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis". This is a Phase 2, multicenter, open-label study in subjects with moderate to severe plaque psoriasis aged 6 to 17 years, inclusive, intended to assess the safety, tolerability, and PK of apremilast with 2 weeks of oral apremilast treatment followed by a 48-week extension of apremilast treatment. Mo...
What is the current status of trial NCT02576678?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2015-10-13. Estimated completion is 2019-07-29.
What conditions does trial NCT02576678 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02576678?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT02576678?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02576678 being conducted?
This trial has 18 study locations across California, Georgia, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
-
Randomized Study of PH-10 for Psoriasis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.